Table 1. Clinical activity of ICIs in relapsed TETs.
Parameter | NCT02364076 (Pembrolizumab) | NCT02607631 (Pembrolizumab) | NCT01772004 (Avelumab) | |||
---|---|---|---|---|---|---|
Thymic carcinoma | Thymoma | Thymic carcinoma | Thymoma | |||
Number of patients | 40 | 7 | 26 | 7 | ||
Response rate (%) | 22.5 | 28.6 | 19.2 | 28.5 | ||
Median PFS (months) | 4.2 | 6.1 | 6.1 | NA | ||
Median OS (months) | 24.9 | NR | 14.5 | NA |
TET, thymic epithelial tumor; PFS, progression-free survival; OS, overall survival; NR, not reached; NA, not available; ICIs, immune checkpoint inhibitors.